8 research outputs found
Establishing cost-effectiveness of genetic targeting of cancer therapies\ud
The clinical benefit of a new genomic instrument, the 70-gene signature\ud
for breast cancer patients, is being evaluated in a randomised clinical\ud
trial. The early, controlled implementation process is supported by a\ud
Constructive Technology Assessment to help decision-making in an\ud
uncertain time of developmen
Establishing cost-effectiveness of genetic targeting of cancer therapies
The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to help decision-making in an uncertain time of development